The FDA is reevaluating GlaxoSmithKline’s blood cancer drug Blenrep following mixed results from two phase 3 trials and mounting concerns about eye-related side effects and dosing. The agency is ...

GLP-1 anti-obesity medications are linked with improvements in testosterone levels and health outcomes for men with obesity or type 2 diabetes, researchers reported in San Francisco at ENDO 2025, the ...

The U.S. Food and Drug Administration's staff reviewers on Tuesday raised safety concerns that GSK's blood cancer drug ...

FDA reviewers have identified high rates of ocular toxicity as GSK looks to place its blood cancer drug back on the market.

Donald Trump has threatened new tariffs on medicines within weeks as he steps up demands for drugmakers to move factories to ...

The usually sluggish FTSE 100 is having a surprisingly good year. But our writer feels there are still potential bargains ...

Britain launched a life sciences sector plan on Wednesday to a mixed response from the pharmaceutical industry, which welcomed proposals to boost R&D but warned it would fail to keep firms competitive ...

Recent health headlines include FDA's eye safety concerns over GSK's cancer drug, escalating malnutrition rates in Gaza ...

From my colleague Drew Joseph: Ahead of an advisory committee meeting Thursday focused on GSK’s multiple myeloma drug Blenrep, the FDA pointed to concerns about the high rates of eye issues that have ...

With the aim of being the largest life sector by 2035 behind only the US and China, the UK government is ramping up commercialisation.

GSK's blood cancer drug, Blenrep, is under the U.S. Food and Drug Administration (USFDA) spotlight, as staff reviewers raised ...

India needs to build a much stronger drug discovery ecosystem to compete globally, says former GSK Pharma MD Annaswamy ...